서브이미지
HOME > 자료실 > 문헌자료

문헌자료

ㆍ 제목 Mayo Collaborative Services v. Prometheus Laboratories, Inc. 사건판결에서 나타난 미국 연방 대법원의 판결 경향
ㆍ 조회수 534 ㆍ 등록일시 2017-01-02 17:07:10
ㆍ 작성자 관리자
ㆍ 첨부파일

 

 발행년

 2012

 구분

 국내학술지

 학술지명

 창작과 권리

 관련링크

 http://scholar.dkyobobook.co.kr/searchDetail.laf?barcode=4010023741099

 

 

 

 

Mayo Collaborative Services v. Prometheus Laboratories, Inc. 사건판결에서 나타난 미국 연방 대법원의 판결 경향

 

 

  • ​저자명

이정아, 배대헌

  • 학술지명

창작과 권리

  • 권호사항

제68호

  • 발행처

세창출판사

  • 자료유형

국내학술지

  • 수록면

71 - 110

  • 언어

Korean

  • 발행년도

2012

 

 

  • Abstract

This paper analyzes the recent United States Supreme Court's decision, Mayo Collaboraive Service v. Prometheus Laboratories, Inc. This decision reversed the United States Court of Appeals for the Federal Circuit's holding that the claims were patentable because they satisfied the machine-or-transformation test. 
In Mayo, the United States Supreme Court held that Prometheus' process was not patent-eligible. Since Prometheus' claims recited the laws of nature -the relationships between concentrations of certain metabolites in the blood and the likelihood that a thiopurine drug dosage would prove ineffective or cause harm- the claimed processes were not patentable. To be patent-eligible, there should be additional features that provide practical assurance that the processes are genuine applications of those laws rather than drafting efforts designed to monopolize the correlations. The three additional steps in the claimed processes were not themselves natural laws but neither were they sufficient to transform the nature of the claims. However, how much of application is necessary to satisfy the patent requirement is still questionable. 
After Mayo, the Court remanded two cases -Association of Molecular v. Myriad, and Ultramercial v. Hulu.- to the United States Court of Appeals for the Federal Circuit. This suggests that the Supreme Court intends Mayo to have a wide-ranging impact in biotech and software cases. In light of Mayo, it is unlikely that the Court will hold Myriad and Ultramercial's claims are patent-eligible based on the Court's precedents.

 

 

 

 

 

 

ㆍ 이전글 특허보호대상으로서 유전자에 대한 고찰 / The Study on Gene as Patentable Subject Matter
ㆍ 다음글 의약의 투여용법과 투여용량의 특허대상적격성 / Patent-eligible subject matter of a dosage regimen and a dose in the Medical Use Invention